Clinical trial
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or…
NCT00234026 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00234026 |
|---|---|
| Title | Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma |
| Official title | Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Gemcitabine for the Treatment of Patients With Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Oct 6, 2005 |
| Last update posted | Jun 5, 2012 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: